Gastro-oesophageal reflux disease: Pathophysiology, diagnosis and medical therapy;Gastro-oesofageale refluxziekte: Pathofysiologie, diagnostiek en medicamenteuze therapie

Nederlands Tijdschrift voor Geneeskunde

Volumn 142, Issue 23, 1998, Pages 1306-1310

  Boermeester, M A ^a   Van Sandick, J W ^a   Van Lanschot, J J B ^a   Boeckxstaens, G E ^a   Tytgat, G N J ^a   Obertop, H ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; PROKINETIC AGENT; PROTECTIVE AGENT; PROTON PUMP INHIBITOR;

BARRETT ESOPHAGUS; ENDOSCOPY; ESOPHAGOGRAPHY; ESOPHAGUS PH; GASTROESOPHAGEAL REFLUX; HUMAN; MANOMETRY; PATIENT COUNSELING; REVIEW;

ANTI-ULCER AGENTS; DIAGNOSIS, DIFFERENTIAL; ESOPHAGEAL DISEASES; ESOPHAGOGASTRIC JUNCTION; ESOPHAGOSCOPY; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; RECURRENCE;

EID: 0032490366     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Ruth M, Mansson I, Sandberg N. The prevalence of symptoms suggestive of esophageal disorders. Scand J Gastroenterol 1991;26:73-81.
2. Gooszen HG, Weidema WF, Ringers J, Horbach JMLM, Masclee AAM, Lamers CBHW. Initial experience with laparoscopic fundoplication in the Netherlands and comparison with an established technique (Belsey Mark IV). Scand J Gastroenterol 1993;200 Suppl: 24-7
3. Ollyo JB, Monnier P, Fontolliet C, Savary M. The natural history, prevalence and incidence of reflux oesophagitis. Gullet 1993;3 Suppl:1-10.
4. Tytgat GNJ. Long-term therapy for reflux esophagitis. N Engl J Med 1995;333:1148-50.
5. McDougall NI, Johnston BT, Kee F, Collins JSA, McFarland RJ, Love AHG. Natural history of reflux oesophagitis: a 10 year follow up of its effect on patient symptomatology and quality of life. Gut 1996;38:481-6.
6. Mittal RK, Holloway RH, Penagini R, Blackshaw LA, Dent J, Transient lower esophageal sphincter relaxation. Gastroenterology 1995;109:601-10.
7. Mittal RK, Balaban DH The esophagogastric junction. N Engl J Med 1997;336:924-32.
8. Ireland AC, Holloway RH, Toouli J, Dent J. Mechanisms underlying the antireflux action of fundoplication. Gut 1993;34:303-8.
9. Howard PJ, Heading RC. Epidemiology of gastro-esophageal reflux disease. World J Surg 1992;16:288-93.
10. Johnson DA, Winters C, Spurling TJ, Chobanian SJ, Cattau jr EL. Esophageal acid sensitivity in Barrett's esophagus. J Clin Gastroenterol 1987;9:23-7.
11. Fennerty MB, Castell D, Fendrick AM, Halpern M, Johnson D, Kahrilas PJ, et al. The diagnosis and treatment of gastroesophageal reflux disease in a managed care environment. Suggested disease management guidelines. Arch Intern Med 1996;156:477-84.
12. Ergun GA, Kahrilas PJ. Clinical applications of esophageal manometry and pH monitoring. Am J Gastroenterol 1996;91:1077-89.
13. Richter JE. Surgery for reflux disease: reflections of a gastroenterologist. N Engl J Med 1992;326:825-7.
14. Reynolds JC. Individualized acute treatment strategies for gastroesophageal reflux disease. Scand J Gastroenterol 1995;213 Suppl: 17-24.
15. Tytgat GNJ, Bianchi Porro G, Feussner H, Pace F, Richter JE, Siewert JR. Long-term strategy for the treatment of gastro-oesophageal reflux disease. Gastroenterol Int 1991;4:21-32.
16. DeVault KR, Castell DO. Current diagnosis and treatment of gastroesophageal reflux disease. Mayo Clin Proc 1994;69:867-76.
17. Sontag SJ. The medical management of reflux esophagitis. Role of antacids and acid inhibition. Gastroenterol Clin North Am 1990;19:683-712.
18. Lundell L, Backman L, Ekström P, Enander LH, Fausa O, Lind T, et al Omeprazole or high-dose ranitidine in the treatment of patients with reflux oesophagitis not responding to 'standard doses' of H2-receptor antagonists. Aliment Pharmacol Ther 1990;4:145-55.
19. Hetzel DJ, Dent J, Reed WD, Narielvala FM, Mackinnon M, McCarthy JH, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988;95: 903-12.
20. Dent J, Yeomans ND, Mackinnon M, Reed W, Narielvala FM, Hetzel DJ, et al. Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety. Gut 1994;35:590-8.
21. Vigneri S, Termini R, Leandro G, Badalamenti S, Pantalena M, Savarino V, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995;333:1106-10.
22. Klinkenberg-Knol EC, Festen HPM, Jansen JBMJ, Lamers CBHW, Nelis F, Snel P, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994;121:161-7.
23. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, Havu N, Festen HPM, Liedman B, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996;334:1018-22.
24. Labenz J, Tillenburg B, Peitz U, Idström JP, Verdu EF, Stolte M, et al. Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. Gastroenterology 1996;110: 725-32
25. Chow WH, Finkle WD, McLauglin JK, Frankl H, Ziel HK, Fraumeni jr JF. The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA 1995;274:474-7
26. Walt RP, Gomes MD, Wood EC, Logan LH, Pounder RE. Effect of daily oral omeprazole on 24 hour intragastric acidity. Br Med J (Clin Res Ed) 1983;287:12-4.
27. Hetzel DJ, Shearman DJC. Omeprazole inhibition of nocturnal gastric secretion in patients with duodenal ulcer. Br J Clin Pharmacol 1984;18:587-90.
28. Fein M, Ireland AP, Ritter MP, Peters JH, DeMeester TR, Bremner CG The contribution of duodenogastric reflux to esophageal injury. Gastroenterology 1996;110:A1124.
29. Kauer WKH, Peters JH, DeMeester TR, Ireland AP, Bremner CG, Hagen JA. Mixed reflux of gastric and duodenal juices is more harmful to the esophagus than gastric juice alone. The need for surgical therapy re-emphasized. Ann Surg 1995;222:525-33.
30. Ireland AP, Peters JH, Smyrk TC, DeMeester TR, Clark GW, Mirvish SS, et al. Gastric juice protects against the development of esophageal adenocarcinoma in the rat. Ann Surg 1996;224:358-71.
31. Alderson D, Welbourn CRB. Laparoscopic surgery for gastrooesophageal reflux disease. Gut 1997;40:565-7.
32. Sampliner RE, Garewal HS, Fennerty MB, Aickin M. Lack of impact of therapy on extent of Barrett's esophagus in 67 patients. Dig Dis Sci 1990;35:93-6.
33. Kruyt PhM, Sandick JW van, Lanschot JJB van, Offerhaus GJA, Tytgat GNJ, Obertop H. Barrett-oesofagus en Barrett-carcinoom. Ned Tijdschr Geneeskd 1997;141:869-73.